Figure 1.

(a) Whole-body iodine-131 scan of patient demonstrating no visible uptake at the moment of disease progression with loss of previous well radioiodine accumulation, and (b) Whole-body scan of the same patient six months after vemurafenib therapy demonstrating intensive uptake in lung metastases (leading to redifferentiation of thyroid cancer cells and restoration of radioiodine uptake).